Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients

Patent metadata

Field	Value
Publication number	US-9707155-B2
Application number	US-201414259286-A
Country	US
Kind code	B2
Filing date	Apr 23, 2014
Priority date	Apr 24, 2013
Publication date	Jul 18, 2017
Grant date	Jul 18, 2017

Abstract

The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, LYXUMIA (lixisenatide), LEMTRADA (alemtuzumab), REGN727/SAR236553 (alirocumab), SAR2405550/BSI-201 (iniparib), OTAMIXABAN (otamixaban), SARILUMAB (sarilumab), LANTUS and LYXUMIA (insulin glargine and lixisenatide) or VISAMERIN/MULSEVO (semuloparin sodium).

First claim

What is claimed is:

1. A pharmaceutical product comprising:
lixisenatide, alemtuzumab, alirocumab, iniparib, otamixaban, sarilumab, insulin glargine and lixisenatide or semuloparin sodium and a pharmaceutically acceptable excipient;
contained within a glass pharmaceutical container comprising a glass composition comprising:
SiO 2 in a an amount greater than or equal to about 72 mol. % and less than or equal to about 78 mol. %;
alkaline earth oxide comprising both MgO and CaO, wherein CaO is present in an amount up to about 1.0 mol. %, and a ratio (CaO (mol. %)/(CaO (mol. %)+MgO (mol. %))) is less than or equal to 0.5;
X mol. % Al 2 O 3 , wherein X is greater than or equal to about 5 mol. % and less than or equal to about 7 mol. %;
Y mol. % alkali oxide, wherein the alkali oxide comprises Na 2 O in an amount greater than about 8 mol. %; and
a ratio of a concentration of B 2 O 3 (mol. %) in the glass container to (Y mol. %-X mol. %) is less than or equal to 0.3.

2. The pharmaceutical product of claim 1 , wherein the pharmaceutical container comprises a compressive stress greater than or equal to 150 MPa.

3. The pharmaceutical product of claim 1 , wherein the pharmaceutical container comprises a compressive stress greater than or equal to 250 MPa.

4. The pharmaceutical product of claim 1 , wherein the pharmaceutical container comprises a depth of layer greater than 30 μm.

5. The pharmaceutical product of claim 1 , wherein the pharmaceutical product comprises increased stability, product integrity, or efficacy.

6. The pharmaceutical product of claim 1 :
wherein the glass pharmaceutical container has a compressive stress greater than or equal to 150 MPa and a depth of layer greater than 10 μm, and wherein the pharmaceutical product comprises increased stability, product integrity, or efficacy.

7. The pharmaceutical product of claim 1 :
wherein the glass pharmaceutical container which is substantially free of boron, and wherein the pharmaceutical product comprises increased stability, product integrity, or efficacy.

8. The pharmaceutical product of claim 7 , wherein the glass pharmaceutical container comprises a compressive stress greater than or equal to 150 MPa and a depth of layer greater than 25 μm.

9. The pharmaceutical product of claim 8 , wherein the glass pharmaceutical container comprises a compressive stress greater than or equal to 300 MPa and a depth of layer greater than 35 μm.

10. The pharmaceutical product of claim 7 , wherein said glass pharmaceutical container comprises a substantially homogeneous inner layer.

11. The pharmaceutical product of claim 10 , wherein said glass pharmaceutical container comprises a compressive stress greater than or equal to 150 MPa and a depth of layer greater than 25 μm.

12. The pharmaceutical product of claim 1 , wherein the pharmaceutical container comprises an internal homogeneous layer.

Assignees

• Corning Inc

Inventors

• Weeks Wendell P
• Schaut Robert Anthony
• Demartino Steven Edward
• Peanasky John Stephen

Classifications

• C03C21/002

  to perform ion-exchange between alkali ions (C03C21/005 takes precedence) · CPC title

• A61K31/4425

  Pyridinium derivatives, e.g. pralidoxime, pyridostigmine · CPC title

• A61K31/166

  having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol · CPC title

• C03C3/087

  containing calcium oxide, e.g. common sheet or container glass · CPC title

• C07K16/248

  IL-6 · CPC title